Keros Therapeutics (NASDAQ:KROS) Upgraded to "Hold" at Wall Street Zen

Key Points

• Wall Street Zen upgraded Keros Therapeutics from “strong sell” to “hold.” The broader analyst consensus is also “hold,” with an average price target of $21.40.
• Keros reported quarterly earnings of $0.70 per share, beating the consensus estimate of a $0.96 loss, and revenue of $40.01 million versus expectations of $14.76 million.
• The board authorized a $5 million share repurchase program, allowing the company to buy back up to 2.3% of its outstanding shares.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "strong sell" rating to a "hold" rating in a report released on Monday, Wall Street Zen reports.

A number of other brokerages also recently commented on KROS. Leerink Partners cut their target price on shares of Keros Therapeutics from $30.00 to $23.00 and set an "outperform" rating on the stock in a research note on Tuesday, August 4th. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price target on shares of Keros Therapeutics in a research report on Tuesday, August 4th. Wells Fargo & Company decreased their price target on shares of Keros Therapeutics from $20.00 to $18.00 and set an "overweight" rating for the company in a research report on Tuesday, August 4th. Zacks Research upgraded Keros Therapeutics from a "strong sell" rating to a "hold" rating in a report on Thursday, August 27th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Keros Therapeutics in a research report on Wednesday, August 12th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Keros Therapeutics presently has a consensus rating of "Hold" and a consensus target price of $21.40.

Keros Therapeutics Stock Performance

KROS opened at $9.36 on Monday. The firm has a 50 day moving average price of $11.18 and a 200 day moving average price of $11.92. The company has a market cap of $185.58 million, a PE ratio of -3.32 and a beta of 1.13. Keros Therapeutics has a 1 year low of $9.26 and a 1 year high of $22.55.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of ($0.96) by $1.66. The firm had revenue of $40.01 million for the quarter, compared to analysts' expectations of $14.76 million. Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.76%. On average, sell-side analysts predict that Keros Therapeutics will post -5.27 earnings per share for the current year.

Keros Therapeutics declared that its Board of Directors has approved a share repurchase program on Wednesday, September 9th that permits the company to buy back $5 million in outstanding shares. This repurchase authorization permits the company to repurchase up to 2.3% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's leadership believes its shares are undervalued.

Insiders Place Their Bets

In other Keros Therapeutics news, insider Lorena Raquel Lerner sold 3,568 shares of the company's stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $10.29, for a total value of $36,714.72. Following the completion of the transaction, the insider directly owned 27,559 shares of the company's stock, valued at $283,582.11. This represents a 11.46% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 5,343 shares of company stock valued at $54,985. Corporate insiders own 12.60% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of KROS. Legal & General Group Plc purchased a new position in Keros Therapeutics in the second quarter valued at about $90,000. PDT Partners LLC purchased a new stake in Keros Therapeutics during the 2nd quarter worth approximately $122,000. Lazard Asset Management LLC acquired a new position in shares of Keros Therapeutics in the 1st quarter valued at approximately $129,000. Diversified Trust Co acquired a new position in shares of Keros Therapeutics in the 3rd quarter valued at approximately $133,000. Finally, Canada Pension Plan Investment Board acquired a new position in shares of Keros Therapeutics in the 2nd quarter valued at approximately $247,000. Institutional investors and hedge funds own 71.56% of the company's stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for diseases caused by dysfunctional signaling in the transforming growth factor-beta (TGF-β) superfamily of proteins. The company uses its research platform to design therapies intended to regulate signaling pathways involved in blood-cell production, bone health and cardiovascular function.

Keros' investigational pipeline has included elritercept (KER-050), an activin receptor type IIA ligand trap being studied for hematologic conditions such as lower-risk myelodysplastic syndromes and myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.